Olio Labs

Combination therapeutics for the world's toughest diseases

Y CombinatorSummer 2023ActiveHealthcareDrug Discovery and Delivery

What they do

Problem

Many complex diseases are poorly treated by single-target drugs because they ignore the body's interconnected protein interactions and can cause significant side effects.

Solution

An AI/ML platform that searches trillions of multi-target drug combinations to design more effective, lower-side-effect combination therapeutics (starting with obesity).

Who it's for

Pharmaceutical and biotechnology companies developing new therapeutics, especially for obesity and other complex diseases.

Founders

David Tingley

Founder

David has over 13 years of experience as a systems neuroscientist and biologist. His interest in systems biology led him to earn a PhD in Neuroscience at New York University and complete postdoctoral research at Harvard. During this time, he published more than 15 scientific articles and uncovered a link between oscillations in brain activity and glucose metabolism in the body (Tingley et al., Nature 2020).

LinkedIn · X

Tom Roseberry

Founder

Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.

LinkedIn · X